Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of Cellm-001 for newly diagnosed glioblastoma
jRCT2031200153Phase 3Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial in glioblastoma (GBM) comparing Cellm-001 arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Started Jan 2021; status: active, not recruiting.
02
Drugs
autologous formalin-fixed tumor vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2031200153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200153.